STOCK TITAN

[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Akero Therapeutics (AKRO) – Form 4 insider transaction

President & CEO Andrew Cheng reported two open-market sales on 10 July 2025 executed under a previously adopted Rule 10b5-1 trading plan dated 16 Aug 2024.

  • 14,686 shares sold at a weighted-average price of $50.57.
  • 15,314 shares sold at a weighted-average price of $51.732.
  • Total shares sold: 30,000; estimated gross proceeds ≈ $1.53 million based on disclosed averages.
  • Post-sale direct holdings: 520,757 common shares (down from 550,757), indicating the CEO retains roughly 94% of his prior stake.

No derivative securities were involved. The filing notes that detailed trade-by-trade pricing is available upon request.

While insider sales can signal caution, the modest size (about 5.5 % of Cheng’s holdings) and the existence of a pre-arranged plan reduce potential negative interpretation. There are no indications of material changes to Akero’s operations or outlook within this filing.

Akero Therapeutics (AKRO) – Transazione insider Form 4

Il Presidente e CEO Andrew Cheng ha comunicato due vendite sul mercato aperto effettuate il 10 luglio 2025, eseguite nell'ambito di un piano di trading Rule 10b5-1 precedentemente adottato il 16 agosto 2024.

  • Vendute 14.686 azioni a un prezzo medio ponderato di 50,57 $.
  • Vendute 15.314 azioni a un prezzo medio ponderato di 51,732 $.
  • Azioni totali vendute: 30.000; proventi lordi stimati ≈ 1,53 milioni di $ basati sulle medie dichiarate.
  • Detenzioni dirette dopo la vendita: 520.757 azioni ordinarie (in calo da 550.757), indicando che il CEO mantiene circa il 94% della sua partecipazione precedente.

Non sono stati coinvolti strumenti derivati. Il deposito segnala che i dettagli dei prezzi per singola transazione sono disponibili su richiesta.

Pur potendo le vendite insider segnalare prudenza, la dimensione contenuta (circa il 5,5% delle partecipazioni di Cheng) e l'esistenza di un piano predefinito riducono interpretazioni negative. Non vi sono indicazioni di cambiamenti sostanziali nelle operazioni o nelle prospettive di Akero all'interno di questo deposito.

Akero Therapeutics (AKRO) – Transacción insider Formulario 4

El presidente y CEO Andrew Cheng informó dos ventas en mercado abierto el 10 de julio de 2025, realizadas bajo un plan de trading Rule 10b5-1 previamente adoptado el 16 de agosto de 2024.

  • 14,686 acciones vendidas a un precio promedio ponderado de $50.57.
  • 15,314 acciones vendidas a un precio promedio ponderado de $51.732.
  • Total de acciones vendidas: 30,000; ingresos brutos estimados ≈ $1.53 millones según los promedios divulgados.
  • Participación directa tras la venta: 520,757 acciones ordinarias (desde 550,757), lo que indica que el CEO conserva aproximadamente el 94% de su participación anterior.

No se involucraron valores derivados. El reporte indica que los precios detallados por operación están disponibles bajo solicitud.

Si bien las ventas de insiders pueden señalar precaución, el tamaño moderado (alrededor del 5.5% de las participaciones de Cheng) y la existencia de un plan preestablecido reducen interpretaciones negativas. No hay indicios de cambios materiales en las operaciones o perspectivas de Akero en este reporte.

Akero Therapeutics (AKRO) – Form 4 내부자 거래 보고

사장 겸 CEO Andrew Cheng은 2025년 7월 10일, 이전에 채택된 2024년 8월 16일자 Rule 10b5-1 거래 계획에 따라 두 건의 공개 시장 매도를 보고했습니다.

  • 14,686주를 가중 평균 가격 $50.57에 매도.
  • 15,314주를 가중 평균 가격 $51.732에 매도.
  • 총 매도 주식: 30,000주; 공개된 평균 가격 기준 예상 총 수익 약 $1.53백만.
  • 매도 후 직접 보유 주식: 520,757 보통주 (기존 550,757주에서 감소), CEO가 이전 지분의 약 94%를 유지함을 나타냄.

파생상품 증권은 포함되지 않았습니다. 제출서류에는 개별 거래별 가격 세부 정보가 요청 시 제공된다고 명시되어 있습니다.

내부자 매도는 신중함을 나타낼 수 있으나, 규모가 작고(Cheng 보유 지분의 약 5.5%) 사전에 설정된 계획에 따른 것이므로 부정적 해석 가능성은 낮습니다. 이 제출서류 내에서는 Akero의 운영이나 전망에 중대한 변화가 있음을 시사하는 내용은 없습니다.

Akero Therapeutics (AKRO) – Transaction d'initié Formulaire 4

Le président-directeur général Andrew Cheng a déclaré deux ventes sur le marché ouvert le 10 juillet 2025, réalisées dans le cadre d'un plan de trading Rule 10b5-1 adopté précédemment le 16 août 2024.

  • 14 686 actions vendues à un prix moyen pondéré de 50,57 $.
  • 15 314 actions vendues à un prix moyen pondéré de 51,732 $.
  • Total des actions vendues : 30 000 ; produit brut estimé ≈ 1,53 million de $ selon les moyennes communiquées.
  • Détention directe après vente : 520 757 actions ordinaires (en baisse par rapport à 550 757), indiquant que le PDG conserve environ 94 % de sa participation précédente.

Aucun instrument dérivé n'a été impliqué. Le dépôt précise que les détails des prix par transaction sont disponibles sur demande.

Bien que les ventes d'initiés puissent indiquer une certaine prudence, la taille modérée (environ 5,5 % des participations de Cheng) et l'existence d'un plan préétabli réduisent l'interprétation négative. Aucun indice de changement important dans les opérations ou les perspectives d'Akero n'est présent dans ce dépôt.

Akero Therapeutics (AKRO) – Form 4 Insider-Transaktion

Präsident & CEO Andrew Cheng meldete zwei Verkäufe am offenen Markt am 10. Juli 2025, ausgeführt im Rahmen eines zuvor angenommenen Rule 10b5-1 Handelsplans vom 16. August 2024.

  • 14.686 Aktien verkauft zu einem gewichteten Durchschnittspreis von 50,57 $.
  • 15.314 Aktien verkauft zu einem gewichteten Durchschnittspreis von 51,732 $.
  • Gesamtverkaufte Aktien: 30.000; geschätzte Bruttoerlöse ≈ 1,53 Millionen $ basierend auf den angegebenen Durchschnittspreisen.
  • Direkter Bestand nach Verkauf: 520.757 Stammaktien (vorher 550.757), was darauf hindeutet, dass der CEO etwa 94 % seines vorherigen Anteils behält.

Es wurden keine Derivate verwendet. Die Meldung weist darauf hin, dass detaillierte Preise pro Einzeltransaktion auf Anfrage verfügbar sind.

Obwohl Insider-Verkäufe Vorsicht signalisieren können, mindert die moderate Größe (etwa 5,5 % von Chengs Bestand) und der vorab festgelegte Plan negative Interpretationen. Es gibt keine Hinweise auf wesentliche Änderungen in Akeros Geschäftstätigkeit oder Ausblick in dieser Meldung.

Positive
  • Rule 10b5-1 plan adoption shows proactive compliance, reducing litigation and perception risk.
  • CEO retains over 520k shares, preserving strong ownership alignment with investors.
Negative
  • Insider sale of 30,000 shares may be perceived as reduced confidence, albeit modest.
  • No accompanying disclosure clarifies use of proceeds or future trading intentions.

Insights

TL;DR: CEO sells 30k shares (≈$1.5 m) under 10b5-1 plan; impact neutral.

The transaction represents a small fraction of Dr. Cheng’s position and was executed through a pre-scheduled plan, limiting signaling value. The remaining 520.8k shares align management incentives with shareholders. No operational data or guidance change accompanies the sale; therefore, it should not materially affect valuation or sentiment absent other news.

TL;DR: Planned sale adheres to governance best practices; low risk.

Use of a Rule 10b5-1 plan adopted well in advance demonstrates procedural compliance and mitigates concerns about informational advantage. The CEO’s continued sizable ownership supports alignment. From a governance lens, the filing is routine and not indicative of unrest or strategic shifts.

Akero Therapeutics (AKRO) – Transazione insider Form 4

Il Presidente e CEO Andrew Cheng ha comunicato due vendite sul mercato aperto effettuate il 10 luglio 2025, eseguite nell'ambito di un piano di trading Rule 10b5-1 precedentemente adottato il 16 agosto 2024.

  • Vendute 14.686 azioni a un prezzo medio ponderato di 50,57 $.
  • Vendute 15.314 azioni a un prezzo medio ponderato di 51,732 $.
  • Azioni totali vendute: 30.000; proventi lordi stimati ≈ 1,53 milioni di $ basati sulle medie dichiarate.
  • Detenzioni dirette dopo la vendita: 520.757 azioni ordinarie (in calo da 550.757), indicando che il CEO mantiene circa il 94% della sua partecipazione precedente.

Non sono stati coinvolti strumenti derivati. Il deposito segnala che i dettagli dei prezzi per singola transazione sono disponibili su richiesta.

Pur potendo le vendite insider segnalare prudenza, la dimensione contenuta (circa il 5,5% delle partecipazioni di Cheng) e l'esistenza di un piano predefinito riducono interpretazioni negative. Non vi sono indicazioni di cambiamenti sostanziali nelle operazioni o nelle prospettive di Akero all'interno di questo deposito.

Akero Therapeutics (AKRO) – Transacción insider Formulario 4

El presidente y CEO Andrew Cheng informó dos ventas en mercado abierto el 10 de julio de 2025, realizadas bajo un plan de trading Rule 10b5-1 previamente adoptado el 16 de agosto de 2024.

  • 14,686 acciones vendidas a un precio promedio ponderado de $50.57.
  • 15,314 acciones vendidas a un precio promedio ponderado de $51.732.
  • Total de acciones vendidas: 30,000; ingresos brutos estimados ≈ $1.53 millones según los promedios divulgados.
  • Participación directa tras la venta: 520,757 acciones ordinarias (desde 550,757), lo que indica que el CEO conserva aproximadamente el 94% de su participación anterior.

No se involucraron valores derivados. El reporte indica que los precios detallados por operación están disponibles bajo solicitud.

Si bien las ventas de insiders pueden señalar precaución, el tamaño moderado (alrededor del 5.5% de las participaciones de Cheng) y la existencia de un plan preestablecido reducen interpretaciones negativas. No hay indicios de cambios materiales en las operaciones o perspectivas de Akero en este reporte.

Akero Therapeutics (AKRO) – Form 4 내부자 거래 보고

사장 겸 CEO Andrew Cheng은 2025년 7월 10일, 이전에 채택된 2024년 8월 16일자 Rule 10b5-1 거래 계획에 따라 두 건의 공개 시장 매도를 보고했습니다.

  • 14,686주를 가중 평균 가격 $50.57에 매도.
  • 15,314주를 가중 평균 가격 $51.732에 매도.
  • 총 매도 주식: 30,000주; 공개된 평균 가격 기준 예상 총 수익 약 $1.53백만.
  • 매도 후 직접 보유 주식: 520,757 보통주 (기존 550,757주에서 감소), CEO가 이전 지분의 약 94%를 유지함을 나타냄.

파생상품 증권은 포함되지 않았습니다. 제출서류에는 개별 거래별 가격 세부 정보가 요청 시 제공된다고 명시되어 있습니다.

내부자 매도는 신중함을 나타낼 수 있으나, 규모가 작고(Cheng 보유 지분의 약 5.5%) 사전에 설정된 계획에 따른 것이므로 부정적 해석 가능성은 낮습니다. 이 제출서류 내에서는 Akero의 운영이나 전망에 중대한 변화가 있음을 시사하는 내용은 없습니다.

Akero Therapeutics (AKRO) – Transaction d'initié Formulaire 4

Le président-directeur général Andrew Cheng a déclaré deux ventes sur le marché ouvert le 10 juillet 2025, réalisées dans le cadre d'un plan de trading Rule 10b5-1 adopté précédemment le 16 août 2024.

  • 14 686 actions vendues à un prix moyen pondéré de 50,57 $.
  • 15 314 actions vendues à un prix moyen pondéré de 51,732 $.
  • Total des actions vendues : 30 000 ; produit brut estimé ≈ 1,53 million de $ selon les moyennes communiquées.
  • Détention directe après vente : 520 757 actions ordinaires (en baisse par rapport à 550 757), indiquant que le PDG conserve environ 94 % de sa participation précédente.

Aucun instrument dérivé n'a été impliqué. Le dépôt précise que les détails des prix par transaction sont disponibles sur demande.

Bien que les ventes d'initiés puissent indiquer une certaine prudence, la taille modérée (environ 5,5 % des participations de Cheng) et l'existence d'un plan préétabli réduisent l'interprétation négative. Aucun indice de changement important dans les opérations ou les perspectives d'Akero n'est présent dans ce dépôt.

Akero Therapeutics (AKRO) – Form 4 Insider-Transaktion

Präsident & CEO Andrew Cheng meldete zwei Verkäufe am offenen Markt am 10. Juli 2025, ausgeführt im Rahmen eines zuvor angenommenen Rule 10b5-1 Handelsplans vom 16. August 2024.

  • 14.686 Aktien verkauft zu einem gewichteten Durchschnittspreis von 50,57 $.
  • 15.314 Aktien verkauft zu einem gewichteten Durchschnittspreis von 51,732 $.
  • Gesamtverkaufte Aktien: 30.000; geschätzte Bruttoerlöse ≈ 1,53 Millionen $ basierend auf den angegebenen Durchschnittspreisen.
  • Direkter Bestand nach Verkauf: 520.757 Stammaktien (vorher 550.757), was darauf hindeutet, dass der CEO etwa 94 % seines vorherigen Anteils behält.

Es wurden keine Derivate verwendet. Die Meldung weist darauf hin, dass detaillierte Preise pro Einzeltransaktion auf Anfrage verfügbar sind.

Obwohl Insider-Verkäufe Vorsicht signalisieren können, mindert die moderate Größe (etwa 5,5 % von Chengs Bestand) und der vorab festgelegte Plan negative Interpretationen. Es gibt keine Hinweise auf wesentliche Änderungen in Akeros Geschäftstätigkeit oder Ausblick in dieser Meldung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cheng Andrew

(Last) (First) (Middle)
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/10/2025 S(1) 14,686 D $50.57(2) 536,071 D
Common Stock 07/10/2025 S(1) 15,314 D $51.732(3) 520,757 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person.
2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.03 to $50.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.06 to $52.05, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Jonathan Young, Attorney-in-Fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Akero Therapeutics (AKRO) shares did CEO Andrew Cheng sell?

He sold 30,000 common shares in two transactions on 07/10/2025.

At what prices were the AKRO shares sold?

Weighted-average prices were $50.57 for 14,686 shares and $51.732 for 15,314 shares.

Does the CEO still hold shares after this sale?

Yes. Post-transaction, Dr. Cheng directly owns 520,757 AKRO shares.

Was the sale part of a pre-arranged trading plan?

Yes, the filing cites a Rule 10b5-1 plan adopted on 08/16/2024.

Are any derivative securities involved in this Form 4?

No derivative acquisitions or dispositions were reported.
Akero Therapeutics

NASDAQ:AKRO

AKRO Rankings

AKRO Latest News

AKRO Latest SEC Filings

AKRO Stock Data

3.68B
71.54M
1.14%
116.23%
11.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO